357953-27-6

Basic information

• Product Name: (4aS,6aS,6bR,10S,12aR)-benzyl 10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate
• Synonyms: (4aS,6aS,6bR,10S,12aR)-benzyl 10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate
• CAS NO: 357953-27-6
• Molecular Weight: 588.871
• Mol File: 357953-27-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (4aS,6aS,6bR,10S,12aR)-benzyl 10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (4aS,6aS,6bR,10S,12aR)-benzyl 10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate(357953-27-6)
• EPA Substance Registry System: (4aS,6aS,6bR,10S,12aR)-benzyl 10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate(357953-27-6)

Safety Data

• Hazardous Substances Data: 357953-27-6(Hazardous Substances Data)

Upstream product

• 508-02-1 Oleanolic acid 
• 100-39-0 benzyl bromide 
• 50-78-2 aspirin 
• 303114-51-4 oleanolic acid benzyl ester 
• 100-44-7 benzyl chloride 
• 4339-72-4 oleanolic acid 3-acetate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 303114-51-4 oleanolic acid benzyl ester 
• 1391817-31-4 C₃₉H₅₄O₅ 
• 218600-52-3 methyl 12-oxoisoxazolo[4,5-b]olean-9⁽¹¹⁾-en-28-oate 
• 1309236-59-6 benzyl 12-oxo-isoxazolo[4,5-b]olean-9⁽¹¹⁾-en-28-oate 
• 1309236-49-4 benzyl 3,12-dioxo-olean-9⁽¹¹⁾-en-28-oate 
• 1309236-46-1 benzyl 3β-hydroxy-12-oxo-olean-9(11)-en-28-oate 

Relevant articles and documents

Oleanolic acid derivative with conjugated diene structure C ring and preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to an oleanolic acid derivative with a conjugated diene structure C ring and a preparation method and application thereof. In particular, the invention also provides a pharmaceutical composition comprising an effective amount of the derivative or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; moreover, the derivative or the pharmaceutically acceptable salt thereof can be used for treating inflammation-related diseases and has antitumor activity, and the safety of the compound is improved or equivalent.

Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents

γ-Lactam is an important structural motif in a large number of biologically active natural products and synthetic small pharmaceutical molecules. However, there is currently no effective approach to construct γ-lactam ring directly from natural rigid polycyclic amides. Herein, we report a facile methodology for synthesis of a new group of olean-28,13β-lactams (10a-j) from their corresponding amides, promoted by an easily available reagent 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), through an intramolecular dehydrogenative C-N coupling reaction via a radical ion mechanism. Biological evaluation indicated that the most active lactam 10h displayed potent antiproliferative activity against human cancer cells but 13.84- to 16.92-fold less inhibitory activity on noncancer cells in vitro. In addition, 10h significantly inhibited the growth of implanted prostate cancer in vivo. Furthermore, 10h induced cell cycle arrest and apoptosis and down-regulated the AKT/mTOR signaling in DU-145 cells. Finally, 10h was more stable in rat plasma and human liver microsomes than CDDO-Me and had little hERG channel inhibitory activity. Collectively, 10h may be a potential antiprostate cancer agent for further investigation.

Novel inhibitors of bacterial biofilms and related methods

Multi-cyclic compounds of chemical structure represented by formula given below and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.